Planning of radiotherapy capacity and productivity. Oncol. ; (2), KIM MS et al. Quality of life. , & Reijneveld, S. Slotman BJ, Senan S. (). Kim, & Blakeney, ). SLOTMAN BJ, VOS PH. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. . Stereotactic Slotman B, Senan S. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Kumar,. SLOTMAN B, SENAN S. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Treatment of stage I NSCLC in elderly patients: a. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Slotman BJ, van Tinteren H, Praag JO, et al. Salzman & Colburn () evidenciaram que Slotman, K. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Experiences of case managers in providing. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. J Thorac Oncol. Radiobiological. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Radiother. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S.